Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huai'er granules (also referred to as Huairu granules) are a standardized aqueous extract of the medicinal fungus *Trametes robiniophila Murr.*, which is approved in China for the adjuvant treatment of various malignancies. The extract contains a complex mixture of polysaccharides, proteins, and minerals that exert anti-tumor effects through multiple pathways, including the induction of apoptosis, inhibition of tumor angiogenesis, and modulation of the host immune system. Specifically, it has been shown to enhance the activity of T lymphocytes and natural killer (NK) cells while suppressing inhibitory signaling pathways such as Wnt/beta-catenin and PI3K/Akt. In clinical practice, it is frequently combined with chemotherapy, radiotherapy, or immune checkpoint inhibitors (e.g., PD-1 inhibitors) to improve survival outcomes and reduce recurrence in patients with hepatocellular carcinoma, breast cancer, and lung cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on huai'er granules.